Eclipsebio Launches AI Platform to Support RNA Therapeutic Development

Eclipsebio, a biotechnology company combining AI-powered sequence design, rapid prototyping, and sequencing-based analytics to support RNA drug development, has introduced eCOMPASS, an artificial intelligence–enabled platform designed to support RNA therapeutic development by integrating computational analysis with laboratory processes. The platform uses a lab-in-the-loop approach, combining AI models with experimental data to guide research and refine results in real time. The system is intended to help scientists design experiments, analyze outcomes, and iterate more efficiently during drug development. The platform combines the design, make, and test core capabilities to create a single integrated workflow.  

Eclipsebio focuses on RNA-based technologies, and the new platform is designed to improve how researchers identify and validate therapeutic targets. By linking AI-driven insights with lab workflows, the company aims to accelerate discovery timelines and reduce trial-and-error processes. Biopharmaceutical companies are increasingly adopting AI to enhance drug discovery and development.

Posted by MedCloudInsider Editors on 04/21/2026